EAU Guidelines on Non–Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update

摘要: Abstract Context and objective To present the 2011 European Association of Urology (EAU) guidelines on non–muscle-invasive bladder cancer (NMIBC). Evidence acquisition Literature published between 2004 2010 diagnosis treatment NMIBC was systematically reviewed. Previous were updated, level evidence (LE) grade recommendation (GR) assigned. synthesis Tumours staged as Ta, T1, or carcinoma in situ (CIS) are grouped NMIBC. Diagnosis depends cystoscopy histologic evaluation tissue obtained by transurethral resection (TUR) papillary tumours multiple biopsies CIS. In lesions, a complete TUR is essential for patient's prognosis. Where initial incomplete where high-grade T1 tumour detected, second should be performed within 2–6 wk. tumours, risks both recurrence progression may estimated individual patients using scoring system risk tables. The stratification into low-, intermediate-, high-risk groups—separately progression—is pivotal to recommending adjuvant treatment. For with low progression, one immediate instillation chemotherapy recommended. Patients an intermediate high receive followed minimum 1 yr bacillus Calmette-Guerin (BCG) intravesical immunotherapy further instillations chemotherapy. Papillary CIS BCG yr. Cystectomy offered highest patients, it at least recommended failure patients. long version available from EAU Web site (www.uroweb.org). Conclusions These abridged updated information incorporation clinical practice.